APLS Fail-to-Deliver

Apellis Pharmaceuticals, Inc. (APLS) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $5.25B, listed on NASDAQ, employing roughly 705 people, carrying a beta of -0.25 to the broader market. Apellis Pharmaceuticals, Inc. Led by Cedric Francois, public since 2017-11-09.

Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.

Latest Date

2026-05-07

Latest FTD Quantity

9.4K

Latest Price

$41.12

30-Day Avg FTD

37.0K

30-Day Total FTD

1.1M

Showing 30 days of SEC fail-to-deliver data for Apellis Pharmaceuticals, Inc..

Learn how fails-to-deliver is reported and how to read the data →